Cargando…

Engineering of a trispecific tumor-targeted immunotherapy incorporating 4-1BB co-stimulation and PD-L1 blockade

Co-stimulatory 4–1BB receptors on tumor-infiltrating T cells are a compelling target for overcoming resistance to immune checkpoint inhibitors, but initial clinical studies of 4–1BB agonist mAbs were accompanied by liver toxicity. We sought to engineer a tri-specific antibody-based molecule that sti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Warmuth, Stefan, Gunde, Tea, Snell, Daniel, Brock, Matthias, Weinert, Christopher, Simonin, Alexandre, Hess, Christian, Tietz, Julia, Johansson, Maria, Spiga, Fabio Mario, Heiz, Robin, Flückiger, Naomi, Wagen, Sandro, Zeberer, Julia, Diem, Dania, Mahler, Dana, Wickihalder, Belinda, Muntwiler, Simone, Chatterjee, Bithi, Küttner, Benjamin, Bommer, Bettina, Yaman, Yasemin, Lichtlen, Peter, Urech, David
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9278964/ https://www.ncbi.nlm.nih.gov/pubmed/35844969 http://dx.doi.org/10.1080/2162402X.2021.2004661

Ejemplares similares

An engineered T-cell engager with selectivity for high mesothelin-expressing cells and activity in the presence of soluble mesothelin
por: Snell, Daniel, et al.
Publicado: (2023)

Design of antibody variable fragments with reduced reactivity to preexisting anti-drug antibodies
por: Johansson, Maria U., et al.
Publicado: (2023)

Trispecific natural killer cell nanoengagers for targeted chemoimmunotherapy
por: Au, Kin Man, et al.
Publicado: (2020)

Generation of a symmetrical trispecific NK cell engager based on a two-in-one antibody
por: Harwardt, Julia, et al.
Publicado: (2023)

Trispecific T-cell engagers for dual tumor-targeting of colorectal cancer
por: Tapia-Galisteo, Antonio, et al.
Publicado: (2022)

Bi- and trispecific immune cell engagers for immunotherapy of hematological malignancies
por: Tapia-Galisteo, Antonio, et al.
Publicado: (2023)

The trispecific DARPin ensovibep inhibits diverse SARS-CoV-2 variants
por: Rothenberger, Sylvia, et al.
Publicado: (2022)

When three is not a crowd: trispecific antibodies for enhanced cancer immunotherapy
por: Tapia-Galisteo, Antonio, et al.
Publicado: (2023)

T-cell redirecting bispecific and trispecific antibodies in multiple myeloma beyond BCMA
por: van de Donk, Niels W.C.J., et al.
Publicado: (2023)

Cancer therapeutic trispecific antibodies recruiting both T and natural killer cells to cancer cells
por: Kimura, Kouki, et al.
Publicado: (2023)

Novel multispecific heterodimeric antibody format allowing modular assembly of variable domain fragments
por: Egan, Timothy J., et al.
Publicado: (2016)

The impact of proline isomerization on antigen binding and the analytical profile of a trispecific anti-HIV antibody
por: Masiero, Alessandro, et al.
Publicado: (2020)

Analysis of [Gossypium capitis-viridis × (G.hirsutum × G.australe)(2)] Trispecific Hybrid and Selected Characteristics
por: Chen, Di, et al.
Publicado: (2015)

Rational design of a trispecific antibody targeting the HIV-1 Env with elevated anti-viral activity
por: Steinhardt, James J., et al.
Publicado: (2018)

Biophysical and biochemical characterization of a VHH-based IgG-like bi- and trispecific antibody platform
por: Pekar, Lukas, et al.
Publicado: (2020)

A Trispecific Anti-HIV Chimeric Antigen Receptor Containing the CCR5 N-Terminal Region
por: Hajduczki, Agnes, et al.
Publicado: (2020)

Trispecific antibody targeting HIV-1 and T cells activates and eliminates latently-infected cells in HIV/SHIV infections
por: Promsote, Wanwisa, et al.
Publicado: (2023)

Evaluation of Preclinical Assays to Investigate an Anthroposophic Pharmaceutical Process Applied to Mistletoe (Viscum album L.) Extracts
por: Baumgartner, Stephan, et al.
Publicado: (2014)

Molecular characterization of novel trispecific ErbB-cMet-IGF1R antibodies and their antigen-binding properties
por: Castoldi, R., et al.
Publicado: (2012)

Co-delivery of novel bispecific and trispecific engagers by an amplicon vector augments the therapeutic effect of an HSV-based oncolytic virotherapy
por: Ravirala, Divya, et al.
Publicado: (2021)

Quantitative systems pharmacology modeling sheds light into the dose response relationship of a trispecific T cell engager in multiple myeloma
por: Abrams, R. E., et al.
Publicado: (2022)

A novel IgG Fc by computer-aided design enhances heavy-chain heterodimerization in bi- or trispecific antibodies
por: Wang, Bo, et al.
Publicado: (2022)

Nanobody-based trispecific T cell engager (Nb-TriTE) enhances therapeutic efficacy by overcoming tumor-mediated immunosuppression
por: Ding, Ziqiang, et al.
Publicado: (2023)

Engineering of Anti-CD133 Trispecific Molecule Capable of Inducing NK Expansion and Driving Antibody-Dependent Cell-Mediated Cytotoxicity
por: Schmohl, Jörg U., et al.
Publicado: (2017)

Search for the radion decay into a Higgs boson pair with $\gamma\gamma +bb, \tau\tau+bb$ and $bb+bb$ final states
por: Gennai, Simone
Publicado: (2004)

Correction for Khan et al., “Targeting the HIV-1 Spike and Coreceptor with Bi- and Trispecific Antibodies for Single-Component Broad Inhibition of Entry”
por: Khan, Salar N., et al.
Publicado: (2019)

A trispecific killer engager molecule against CLEC12A effectively induces NK cell mediated killing of AML cells
por: Arvindam, Upasana Sunil, et al.
Publicado: (2020)

First-in-class trispecific VHH-Fc based antibody with potent prophylactic and therapeutic efficacy against SARS-CoV-2 and variants
por: Titong, Allison, et al.
Publicado: (2022)

bbH
por: Asawatangtrakuldee, Chayanit
Publicado: (2022)

Trispecific killer engager 161519 enhances natural killer cell function and provides anti-tumor activity against CD19-positive cancers
por: Cheng, Ying, et al.
Publicado: (2020)

Design of a Trispecific Checkpoint Inhibitor and Natural Killer Cell Engager Based on a 2 + 1 Common Light Chain Antibody Architecture
por: Bogen, Jan P., et al.
Publicado: (2021)

Systemic Delivery of mPEG‐Masked Trispecific T‐Cell Nanoengagers in Synergy with STING Agonists Overcomes Immunotherapy Resistance in TNBC and Generates a Vaccination Effect
por: Shen, Ming, et al.
Publicado: (2022)

A Novel Her2/VEGFR2/CD3 trispecific antibody with an optimal structural design showed improved T-cell-redirecting antitumor efficacy
por: Liu, Dong, et al.
Publicado: (2022)

ATLAS H(bb)
por: Scanlon, Tim
Publicado: (2017)

The Bb real book.
Publicado: (2009)

Higgs to bb in ATLAS
por: Lee, J S H
Publicado: (2013)

Higgs to bb in ATLAS
por: Clark, P J
Publicado: (2012)

Activation of distinct antiviral T-cell immunity: A comparison of bi- and trispecific T-cell engager antibodies with a chimeric antigen receptor targeting HBV envelope proteins
por: Debelec-Butuner, Bilge, et al.
Publicado: (2022)

In silico and phylogenetic analyses of partial BbRAP-1, BbCP2, BbSBP-4 and BbβTUB gene sequences of Babesia bovis isolates from cattle in South Africa
por: Mtshali, Phillip Senzo, et al.
Publicado: (2017)

Measurement of the production rate of bb(bar) quark pairs from gluons and bb(bar)bb(bar) events in hadronic Z^0 decays
por: CERN. Geneva
Publicado: (1999)

Cannot write session to /tmp/vufind_sessions/sess_6sfnnarlbhvjm63j3f7hbk76os